Rencord Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 25-06-2024
- Paid Up Capital ₹ 0.22 M
as on 25-06-2024
- Company Age 13 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 49.57%
(FY 2020)
- Profit 87.38%
(FY 2020)
- Ebitda 209.28%
(FY 2020)
- Net Worth 70.39%
(FY 2020)
- Total Assets 80.85%
(FY 2020)
About Rencord Life Sciences
The Corporate was formerly known as Concord Medipharma Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.22 M, as per Ministry of Corporate Affairs (MCA) records.
Satyajit Singh, Tushar Gupta, and Abhishek Trivedi serve as directors at the Company.
- CIN/LLPIN
U85191UP2011PTC043919
- Company No.
043919
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Mar 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Kanpur Nagar, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Rencord Life Sciences Private Limited offer?
Rencord Life Sciences Private Limited offers a wide range of products and services, including Mineral Supplement, Calcium Tablet, Cardiovascular Drugs & Medication, Kidney Drugs, Health Conditions, Kidney Care, Vitamins & Supplements, Mineral Supplements.
Who are the key members and board of directors at Rencord Life Sciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Satyajit Singh  | Director | 10-Mar-2011 | Current |
| Abhishek Trivedi | Director | 21-Jan-2013 | Current |
| Tushar Gupta | Director | 21-Jan-2013 | Current |
Financial Performance and Corporate Structure Insights of Rencord Life Sciences.
Rencord Life Sciences Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 49.57% increase. The company also saw a substantial improvement in profitability, with a 87.38% increase in profit. The company's net worth Soared by an impressive increase of 70.39%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rencord Life Sciences?
In 2018, Rencord Life Sciences had a promoter holding of 90.91% and a public holding of 9.09%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Rencord Life Sciences?
Rencord Life Sciences has a workforce of 33 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
As of Apr 25, 2013, Rencord Life Sciences has raised a total of ₹ 0.1 M, with the most recent deal valued at ₹ 0.1 M. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
_PRIVATE_LIMITED_354462.webp){kind=small}
